KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guerin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)

被引：2
|
作者：
Shariat, S. F. [1 ]
Steinberg, G. [2 ]
Kamat, A. M. [3 ]
Shore, N. D. [4 ]
Alanee, S. [5 ,6 ]
Nishiyama, H. [7 ]
Nam, K. [8 ]
Godwin, J. L. [8 ]
Kapadia, E. [8 ]
Hahn, N. [9 ]
机构：
[1] Med Univ Vienna, Urol, Vienna, Austria
[2] NYU Langone Hlth, Urol, New York, NY USA
[3] Univ Texas MD Anderson Canc Ctr, Urol, Houston, TX 77030 USA
[4] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA
[5] Michigan State Univ, Urol, Detroit, MI USA
[6] Michigan State Univ, Detroit Med Ctr, Detroit, MI USA
[7] Univ Tsukuba, Urol, Tsukuba, Ibaraki, Japan
[8] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[9] Johns Hopkins Univ, Sch Med, Med Oncol, Baltimore, MD USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
718TiP
引用
收藏
页码：S723 / S723
页数：1
相关论文
共 50 条
  • [41] LACTOCOCCUS LACTIS SECRETING ATTENUATED RECOMBINANT STAPHYLOCOCCAL ENTEROTOXIN B (RSEB) EXCEEDS BACILLUS CALMETTE-GUERIN (BCG) IN THE TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Reis, Leonardo
    Castilho, Mariana
    Mobilon, Cristiane
    da Silveira, Wanderley
    Azevedo, Vasco
    Favaro, Wagner
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04): : E217 - E218
  • [42] SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guerin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)
    Necchi, A.
    Catto, J. W. F.
    Powles, T. B.
    Guerrero-Ramos, F.
    Simone, G.
    Shore, N. D.
    Salinas, J.
    Merseburger, A. S.
    Roumiguie, M.
    Kitamura, H.
    Morris, D.
    Wei, Q.
    Korkes, F.
    Hasan, M.
    Jin, S.
    Maffeo, J.
    Hammond, C.
    Sweiti, H.
    Somer, R.
    Chang, S. S.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1224 - S1224
  • [43] Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guerin for patients with high-risk non-muscle invasive bladder cancer
    Jamil, Marcus L.
    Deebajah, Mustafa
    Sood, Akshay
    Robinson, Kathy
    Rao, Krishna
    Sana, Sherjeel
    Alanee, Shaheen
    [J]. BMJ OPEN, 2019, 9 (07):
  • [44] Impact of Bacillus Calmette-Guerin (BCG) shortage on the management of high risk non-muscle invasive bladder cancer: a single centre study
    Huang, D.
    Perera, M.
    Khan, M.
    Lawrentschuk, N.
    Newbold, R.
    Sengupta, S.
    [J]. BJU INTERNATIONAL, 2018, 121 : 82 - 83
  • [45] THE EFFECTS OF SEQUENTIAL MITOMYCIN AND BACILLUS CALMETTE-GUERIN TREATMENT VERSUS BACILLUS CALMETTE-GUERIN MONOTHERAPY IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER: MITO-BCG (EUDRACT-2017-004540-37)
    De Nunzio, Cosimo
    Leonardo, Costantino
    Carbone, Antonio
    Pastore, Antonio Luigi
    Lombardo, Riccardo
    Nacchia, Antonio
    Cicione, Antonio
    Turchi, Beatrice
    Tema, Giorgia
    Tubaro, Andrea
    [J]. JOURNAL OF UROLOGY, 2023, 209 : E876 - E876
  • [46] Recurrence-free survival in patients on statins with high-risk non-muscle invasive urinary bladder cancer following intravesical Bacillus Calmette-Guerin (BCG)
    Hillen, M.
    Blackmur, J.
    Jones, P.
    Nabi, G.
    [J]. SCOTTISH MEDICAL JOURNAL, 2016, 61 (01) : NP26 - NP26
  • [47] THE BURDEN OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER AMONG PATIENTS TREATED WITH BACILLUS CALMETTE-GUERIN
    Kopenhafer, L.
    Chang, J.
    Thompson, A.
    Sikirica, S.
    Masters, E. T.
    Cappelleri, J. C.
    Peck, E. Y.
    Maculaitis, M. C.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S557 - S557
  • [48] HEALTHCARE RESOURCE USE (HCRU) OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS POST BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE STATUS IN MULTIPLE COUNTRIES
    Broughton, E.
    Chun, D.
    Gooden, K.
    Mycock, K.
    Rajkovic, I
    Taylor-Stokes, G.
    [J]. VALUE IN HEALTH, 2020, 23 : S484 - S485
  • [49] Combination therapy in high-risk non-muscle invasive bladder cancer (HR-NMIBC) with and without BCG prior treatment
    Rexer, H.
    Ohlmann, C. -H.
    Grimm, M. -O.
    [J]. UROLOGIE, 2023, 62 (03): : 338 - 339
  • [50] Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC)
    Naim B Farah
    Rami Ghanem
    Mahmoud Amr
    [J]. BMC Urology, 14
12345